MyMetabolon Login
© 2021 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Microbiome
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
    • Publications
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
    • Publications
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data
22Mar

How Metabolomics Can Raise the Bar in Drug Development

March 22, 2022 Metabolon Drug Development, Working with Metabolon 22
An Interview with Metabolon Chief Scientific Officer Ranga Sarangarajan, Ph.D. So why has this recognized R&D leader now chosen to focus on metabolomics? We sat down with Ranga to get his take on this rapidly growing technology and the potential it holds to propel drug development.
Read more
06Jan

Overcoming the Limitations of Mass Spectrometry Across Datasets

January 6, 2022 Metabolon Blog, Capabilities, Working with Metabolon 54
Metabolon implemented solutions to overcome some of the limitations of MS-based metabolomics while maximizing longitudinal reproducibility. At Metabolon, we implemented solutions based on data normalization and quality control (QC) as critical data processing components to improve data quality and reduce the non-biological variation in the samples. These solutions allow us to overcome some of the limitations of MS-based metabolomics while maximizing longitudinal reproducibility.
Read more
06Dec

Bile acid quantification provides insight into the mechanism of action for the treatment of NASH

December 6, 2021 Metabolon Biomarkers, Drug Development 59
Previous studies have shown that elevated bile acid concentrations are associated with the presence and severity of liver disorders. Given the link between bile acids and metabolic regulation, there is growing interest in understanding how bile acid dysregulation may contribute to NASH pathogenesis and progression.
Read more
17Nov

Event: Microbiome Connect: Gut Therapeutics

November 17, 2021 MetabolonDesign Blog, Events 97
Microbiome Connect: Gut Therapeutics will bring you essential solutions to the array of challenges operating in the microbiome field. The event will facilitate your discussions, uniting academics, biotechs and other industry stakeholders to share their exclusive research and innovation. Hear from big pharma to understand what they look for in a partner.
Read more
01Sep

Metabolomics Drives Identification of Rare Disease Signatures and Diagnoses

September 1, 2021 Metabolon Biomarkers, Capabilities, Drug Development, Precision Medicine 54
Rare diseases represent a unique challenge in clinical medicine. These diseases signify that few people have these diseases and even fewer have a successful diagnosis. Rare diseases are classified in many categories, including metabolic diseases, rare cancers, autoimmune diseases, blood disorders, digestive diseases, endocrine system disorders, nervous system diseases, reproductive disorders, and musculoskeletal diseases.
Read more
03Aug

Uncovering the metabolic basis for population differences in the immune response to malaria.

August 3, 2021 Metabolon Biomarkers, Blog, Omics 90
Malaria is a global health epidemic, with an estimated 229 million cases per year resulting in over 400, 000 deaths with the majority of these deaths being in children under the age of 5. The vast majority of cases in sub-Saharan Africa are caused by the Plasmodium falciparum parasite and transmitted via mosquitos. There is currently no approved vaccine for malaria and antimalarial drug resistance is a growing concern. There is hope that a better understanding of the interactions of the parasite and host metabolism could yield better treatment options.
Read more
21Jul

New Hope for Rare Disease Treatments

July 21, 2021 Metabolon Biomarkers, Drug Development, Precision Medicine 74
The number of rare diseases identified increases with each passing year due to the advent of deeper genome sequencing for patients, characterization of metabolic pathways, and identification/stratification of patients that historically were thought to have other diseases. Metabolomics is uniquely situated to identify biomarkers of disease for numerous rare diseases because it can identify the small molecule profiles of individual patients and link the changes to specific genetic mutations.
Read more
20May

Evaluating Metabolite Stability of Blood Samples for Clinical Applications

May 20, 2021 Metabolon Capabilities, Working with Metabolon 63
Metabolon’s extensive work establishes criteria for evaluating metabolite stability in clinical metabolomic applications and provides guidelines for disqualifying unstable metabolites deriving from sample handling and processing in clinical metabolomic studies to ensure pre-analytical compliance.
Read more
28Apr

Metabolomics and Shotgun Metagenomics Reveal Evidence That Glyphosate Exposure Affects the Gut Microbiome

April 28, 2021 Metabolon Biomarkers, Capabilities, Microbiome 76
A multi-omics approach provides valuable insights for investigating complex areas of science to enhance our understanding while Metabolon’s platform delivers interpretive depth not possible elsewhere. Additionally, the profiling of multiple matrices allowed for analysis of both microbiome derived compounds as well as how those changes may be reflected systemically, giving the work a much broader impact.
Read more
27Apr

Metabolon’s Validation of Dried Blood Spot (DBS) Cards for Metabolomics Analysis

April 27, 2021 Metabolon Capabilities, Population Health, Precision Medicine, Working with Metabolon 69
DBS is a valuable and convenient sampling option to drive metabolomics research forward. In this Q&A section, we asked Kelli Goodman, Staff Scientist at Metabolon, to address some of the common questions regarding the use of DBS samples for metabolomics analysis.
Read more
    123…7

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Quality Assurance
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events
  • Publications

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2022 Metabolon, Inc. All rights reserved. Privacy & Terms

in